Antibodies.com, a trusted provider of high-quality biological reagents for life science researchers, announces the expansion of its UK headquarters with a move to Cambridge Technopark to accommodate the company’s rapid growth.
The new 5000 sqft site is five times larger than its previous premises and has been designed to house increased operational capabilities and broaden access to its range of high-quality reagents and products that support accelerated discovery and development of antibody therapeutics.
Antibodies.com has seen a period of sustained growth and rapid increase in demand for its products globally during the past 5 years, tripling its customer base and now serving more than 5000 research institutions globally.
With a catalogue of more than 100,000 products, including primary and secondary antibodies, proteins and ELISA kits, Antibodies.com serves researchers in 100-plus countries.
Located on Cambridge Technopark, in Cambridge’s biotech hub, the new site features advanced laboratory spaces, a modern logistics area to facilitate enhanced inventory management, and expanded research and development capabilities.
Enabling streamlined workflows and upgraded infrastructure, the new facilities will further strengthen order fulfilment, delivering reagents to customers faster.
Antibodies.com has facilities in Cambridge (UK), Stockholm (Sweden) and St. Louis (US). The newly relocated UK headquarters provide dynamic and collaborative workspaces with shared meeting areas, informal breakout zones, and designated office spaces.
The central Cambridge location offers easy access to local transport options and designated cycle storage to encourage sustainable travel, offering an attractive working location for both the team and visiting customers.
Dr Stewart Newlove (pictured), CTO and founder of Antibodies.com, said: “We are proud to take this significant step forward with our new Cambridge headquarters."
"This move positions us at the centre of the global life sciences community and will enable us to enhance the excellent service our customers have come to expect, scale with global demand, and continue supporting innovation in the discovery and development of antibody therapeutics.”